This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ChromaDex (CDXC) Jumps: Stock Rises 7.7%
by Zacks Equity Research
ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Abeona's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher
by Zacks Equity Research
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Aravive (ARAV) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
by Zacks Equity Research
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
Is Abeona Therapeutics (ABEO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Abeona Therapeutics (ABEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Abeona Therapeutics (ABEO) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Abeona Therapeutics (ABEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abeona Treats First Patient in Pivotal Gene Therapy Study
by Zacks Equity Research
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
Is Earthstone (ESTE) Likely to Beat Q4 Earnings Estimates?
by Zacks Equity Research
Earthstone Energy's (ESTE) fourth-quarter earnings are likely to have been aided by higher oil production.
Factors to Know Ahead of Talos Energy's (TALO) Q4 Earnings
by Zacks Equity Research
Talos Energy's (TALO) fourth-quarter earnings are expected to have taken a hit from lower realized commodity prices.
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
Is the Options Market Predicting a Spike in Abeona (ABEO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
US Dollar Flexes Muscles Against Other Currencies: 5 Winners
by Tirthankar Chakraborty
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
Coronavirus to Hit Apple Sales: Invest in Domestic Producers
by Tirthankar Chakraborty
With the coronavirus threat increasing, it's quite evident that companies having significant exposure to China and the global economy are vulnerable. However, domestic producers of goods should remain unaffected.
Will Abeona Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Are Options Traders Betting On A Big Move In Abeona Therapeutics (ABEO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Abeona Therapeutics (ABEO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -25.64% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Abeona Therapeutics (ABEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Earnings Preview: Abeona Therapeutics (ABEO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.